Cel-Sci Corporation (CVM): Price and Financial Metrics
GET POWR RATINGS... FREE!
CVM Stock Price Chart Interactive Chart >
CVM Price/Volume Stats
|Current price||$2.74||52-week high||$6.51|
|Prev. close||$2.67||52-week low||$1.88|
|Day high||$2.76||Avg. volume||121,417|
|50-day MA||$2.63||Dividend yield||N/A|
|200-day MA||$3.40||Market Cap||119.68M|
Cel-Sci Corporation (CVM) Company Bio
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Most Popular Stories View All
CVM Latest News Stream
|Loading, please wait...|
CVM Latest Social Stream
View Full CVM Social Stream
Latest CVM News From Around the Web
Below are the latest news stories about CEL SCI CORP that investors may wish to consider to help them evaluate CVM as an investment opportunity.
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Fiscal Year 2022 Financial Results On December 28, 2022, CEL-SCI Corporation (NYSE:CVM) submitted its fiscal year 2022 Form 10-K with the SEC concurrent with a press release announcing fiscal year 2022 results. Since our last update in August, CEL-SCI has participated in multiple scientific conferences and presented posters and
CEL-SCI Corporation (AMEX:CVM) marked $2.35 per share on Friday, up from a previous closing price of $2.20. While CEL-SCI Corporation has overperformed by 6.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CVM fell by -68.75%, with highs and lows ranging from $7.91 to $1.88, whereas […]
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments. Clinical and Corporate Developments: CEL-SCI’s main focus throughout fiscal year 2022 has been to complete and submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of Multikine*
Cel-Sci Corporation found using ticker (CVM) now have 2 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 17 and 13 and has a mean target at 15. Now with the previous closing price of 2.9 this would indicate that there is a potential upside of 417.2%. The 50 day MA is 3.22 and the 200 moving average now moves to 3.77. The market cap for the company is $123m. You can visit the company''s website by visiting: https://cel-sci.com [stock_market_widget type="chart" template="basic" color="green" assets="CVM" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $635m based on the market concensus. 0 This article Cel-Sci Corporation – Consensus Indicates Poten...
10-Year Phase 3 Trial Shows CEL-SCI''s Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
CEL-SCI Corporation (NYSE: CVM ) said that its 10-year Phase 3 trial showed that Multikine immunotherapy significantly extended the lives of patients with locally advanced primary squamous cell carcinoma of the head and neck (SCCHN). The company says that current drug therapies for SCCHN from Merck & Co Inc (NYSE: MRK ) and Bristol Myers Squibb & Co (NYSE: BMS ) are approved as a last resort. The Multikine treated study … Full story available on Benzinga.com
CVM Price Returns